



THE JOURNAL OF
CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: A Systematic Review of the Evidence for Medical Marijuana in Psychiatric Indications

Author(s): Samuel T. Wilkinson, MD; Rajiv Radhakrishnan, MD; and Deepak Cyril D'Souza, MD

DOI Number: [dx.doi.org/10.4088/JCP.15r10036](https://doi.org/10.4088/JCP.15r10036)

List of Supplementary Material for the article

Supplementary References

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

Supplementary References

- SR1. Margulies JE, Hammer RP Jr. Delta 9-tetrahydrocannabinol alters cerebral metabolism in a biphasic, dose-dependent manner in rat brain. *Eur J Pharmacol*. 1991;202(3):373–378. doi:10.1016/0014-2999(91)90281-T PubMed
- SR2. Malinowska B, Baranowska-Kuczko M, Schlicker E. Triphasic blood pressure responses to cannabinoids: do we understand the mechanism? *Br J Pharmacol*. 2012;165(7):2073–2088. doi:10.1111/j.1476-5381.2011.01747.x PubMed
- SR3. Katsidoni V, Kastellakis A, Panagis G. Biphasic effects of Δ9-tetrahydrocannabinol on brain stimulation reward and motor activity. *Int J Neuropsychopharmacol*. 2013;16(10):2273–2284. doi:10.1017/S1461145713000709 PubMed
- SR4. Metna-Laurent M, Soria-Gómez E, Verrier D, et al. Bimodal control of fear-coping strategies by CB₁ cannabinoid receptors. *J Neurosci*. 2012;32(21):7109–7118. doi:10.1523/JNEUROSCI.1054-12.2012 PubMed
- SR5. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. *Physiol Rev*. 2003;83(3):1017–1066. doi:10.1152/physrev.00004.2003 PubMed
- SR6. Piomelli D. The molecular logic of endocannabinoid signalling. *Nat Rev Neurosci*. 2003;4(11):873–884. doi:10.1038/nrn1247 PubMed
- SR7. Wilson RI, Nicoll RA. Endocannabinoid signaling in the brain. *Science*. 2002;296(5568):678–682. doi:10.1126/science.1063545 PubMed
- SR8. Howlett AC, Johnson MR, Melvin LS, et al. Nonclassical cannabinoid analgetics inhibit adenylate cyclase: development of a cannabinoid receptor model. *Mol Pharmacol*. 1988;33(3):297–302. PubMed
- SR9. Pan X, Ikeda SR, Lewis DL. Rat brain cannabinoid receptor modulates N-type Ca²⁺ channels in a neuronal expression system. *Mol Pharmacol*. 1996;49(4):707–714. PubMed
- SR10. Brunnauer A, Segmiller FM, Volkamer T, et al. Cannabinoids improve driving ability in a Tourette's patient. *Psychiatry Res*. 2011;190(2-3):382. doi:10.1016/j.psychres.2011.05.033 PubMed
- SR11. Hasan A, Rothenberger A, Münchau A, et al. Oral delta 9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. *J Clin Psychopharmacol*. 2010;30(2):190–192. doi:10.1097/JCP.0b013e3181d236ec PubMed
- SR12. Müller-Vahl KR, Schneider U, Kolbe H, et al. Treatment of Tourette's syndrome with delta-9-tetrahydrocannabinol. *Am J Psychiatry*. 1999;156(3):495. PubMed
- SR13. Müller-Vahl KR, Schneider U, Emrich HM. Combined treatment of Tourette syndrome with Δ9-THC and dopamine receptor antagonists. *Journal of Cannabis Therapeutics*. 2002;2(3-4):145–154. doi:10.1300/J175v02n03_10
- SR14. Hemming M, Yellowlees PM. Effective treatment of Tourette's syndrome with marijuana. *J Psychopharmacol*. 1993;7(4):389–391. doi:10.1177/026988119300700411 PubMed
- SR15. Sandyk R, Awerbuch G. Marijuana and Tourette's syndrome. *J Clin Psychopharmacol*. 1988;8(6):444–445. doi:10.1097/00004714-198812000-00021 PubMed
- SR16. Mikocka-Walus AA, Turnbull DA, Moulding NT, et al. Controversies surrounding the comorbidity of depression and anxiety in inflammatory bowel disease patients: a literature review. *Inflamm Bowel Dis*. 2007;13(2):225–234. doi:10.1002/ibd.20062 PubMed
- SR17. Cámara RJ, Ziegler R, Begré S, et al; Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS) group. The role of psychological stress in inflammatory bowel disease: quality assessment of methods of 18 prospective studies and suggestions for future research. *Digestion*. 2009;80(2):129–139. doi:10.1159/000226087 PubMed
- SR18. Bragatti JA, Torres CM, Londero RG, et al. Prevalence of psychiatric comorbidities in temporal lobe epilepsy in a Southern Brazilian population. *Arq Neuropsiquiatr*. 2011;69(2A):159–165. doi:10.1590/S0004-282X2011000200003 PubMed
- SR19. Gaitatzis A, Trimble MR, Sander JW. The psychiatric comorbidity of epilepsy. *Acta Neurol Scand*. 2004;110(4):207–220. doi:10.1111/j.1600-0404.2004.00324.x PubMed
- SR20. Nuti A, Ceravolo R, Piccinni A, et al. Psychiatric comorbidity in a population of Parkinson's disease patients. *Eur J Neurol*. 2004;11(5):315–320. doi:10.1111/j.1468-1331.2004.00781.x PubMed
- SR21. Marsh L, Williams JR, Rocco M, et al. Psychiatric comorbidities in patients with Parkinson disease and psychosis. *Neurology*. 2004;63(2):293–300. doi:10.1212/01.WNL.0000129843.15756.A3 PubMed
- SR22. Argoff CE. The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach. *Clin J Pain*. 2007;23(1):15–22. doi:10.1097/01.aip.0000210945.27052.b3 PubMed
- SR23. Radat F, Margot-Duclot A, Attal N. Psychiatric co-morbidities in patients with chronic peripheral neuropathic pain: a multicentre cohort study. *Eur J Pain*. 2013;17(10):1547–1557. PubMed
- SR24. Hill KP. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. *JAMA*. 2015;313(24):2474–2483. doi:10.1001/jama.2015.6199 PubMed
- SR25. Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2014;82(17):1556–1563. doi:10.1212/WNL.0000000000000363 PubMed
- SR26. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. *JAMA*. 2015;313(24):2456–2473. doi:10.1001/jama.2015.6358 PubMed
- SR27. Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. *Rheumatology (Oxford)*. 2006;45(1):50–52. doi:10.1093/rheumatology/kei183 PubMed
- SR28. Centonze D, Mori F, Koch G, et al. Lack of effect of cannabis-based treatment on clinical and laboratory measures in multiple sclerosis. *Neurol Sci*. 2009;30(6):531–534. doi:10.1007/s10072-009-0136-5 PubMed
- SR29. Rog DJ, Nurmikko TJ, Friede T, et al. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. *Neurology*. 2005;65(6):812–819. doi:10.1212/01.wnl.0000176753.45410.8b PubMed
- SR30. Zajicek J, Fox P, Sanders H, et al; UK MS Research Group. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. *Lancet*. 2003;362(9395):1517–1526. doi:10.1016/S0140-6736(03)14738-1 PubMed
- SR31. Zajicek JP, Hobart JC, Slade A, et al; MUSEC Research Group. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. *J Neurol Neurosurg Psychiatry*. 2012;83(11):1125–1132. doi:10.1136/jnnp-2012-302468 PubMed

- SR32. Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. *Pain*. 2004;112(3):299–306. doi:10.1016/j.pain.2004.09.013 PubMed
- SR33. Langford RM, Mares J, Novotna A, et al. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. *J Neurol*. 2013;260(4):984–997. doi:10.1007/s00415-012-6739-4 PubMed
- SR34. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. *Neurology*. 2007;68(7):515–521. doi:10.1212/01.wnl.0000253187.66183.9c PubMed
- SR35. Corey-Bloom J, Wolfson T, Gamst A, et al. Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial. *CMAJ*. 2012;184(10):1143–1150. doi:10.1503/cmaj.110837 PubMed
- SR36. Ware MA, Wang T, Shapiro S, et al. Smoked cannabis for chronic neuropathic pain: a randomized controlled trial. *CMAJ*. 2010;182(14):E694–E701. doi:10.1503/cmaj.091414 PubMed
- SR37. Fan F, Compton DR, Ward S, et al. Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. *J Pharmacol Exp Ther*. 1994;271(3):1383–1390. PubMed
- SR38. De Vry J, Jentzsch KR, Kuhl E, et al. Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development. *Behav Pharmacol*. 2004;15(1):1–12. doi:10.1097/00008877-200402000-00001 PubMed
- SR39. Hampson RE, Simeral JD, Kelly EJ, et al. Tolerance to the memory disruptive effects of cannabinoids involves adaptation by hippocampal neurons. *Hippocampus*. 2003;13(5):543–556. doi:10.1002/hipo.10081 PubMed
- SR40. Romero J, Garcia-Palomero E, Castro JG, et al. Effects of chronic exposure to delta9-tetrahydrocannabinol on cannabinoid receptor binding and mRNA levels in several rat brain regions. *Brain Res Mol Brain Res*. 1997;46(1–2):100–108. doi:10.1016/S0169-328X(96)00277-X PubMed
- SR41. D'Souza DC, Ranganathan M, Braley G, et al. Blunted psychotomimetic and amnesic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. *Neuropsychopharmacology*. 2008;33(10):2505–2516. doi:10.1038/sj.npp.1301643 PubMed
- SR42. Ranganathan M, Braley G, Pittman B, et al. The effects of cannabinoids on serum cortisol and prolactin in humans. *Psychopharmacology (Berl)*. 2009;203(4):737–744. doi:10.1007/s00213-008-1422-2 PubMed
- SR43. Ramaekers JG, Kauert G, Theunissen EL, et al. Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. *J Psychopharmacol*. 2009;23(3):266–277. doi:10.1177/0269881108092393 PubMed
- SR44. Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. *Ann N Y Acad Sci*. 1976;282:221–239. doi:10.1111/j.1749-6632.1976.tb49901.x PubMed
- SR45. Jones RT, Benowitz NL, Herning RI. Clinical relevance of cannabis tolerance and dependence. *J Clin Pharmacol*. 1981;21(suppl):143S–152S. doi:10.1002/j.1552-4604.1981.tb02589.x PubMed
- SR46. Haney M, Ward AS, Comer SD, et al. Abstinence symptoms following oral THC administration to humans. *Psychopharmacology (Berl)*. 1999;141(4):385–394. doi:10.1007/s002130050848 PubMed
- SR47. Wiesbeck GA, Schuckit MA, Kalmijn JA, et al. An evaluation of the history of a marijuana withdrawal syndrome in a large population. *Addiction*. 1996;91(10):1469–1478. doi:10.1111/j.1360-0443.1996.tb02251.x PubMed
- SR48. Budney AJ, Hughes JR, Moore BA, et al. Marijuana abstinence effects in marijuana smokers maintained in their home environment. *Arch Gen Psychiatry*. 2001;58(10):917–924. doi:10.1001/archpsyc.58.10.917 PubMed
- SR49. Haney M, Ward AS, Comer SD, et al. Abstinence symptoms following smoked marijuana in humans. *Psychopharmacology (Berl)*. 1999;141(4):395–404. doi:10.1007/s002130050849 PubMed
- SR50. Georgotas A, Zeidenberg P. Observations on the effects of four weeks of heavy marijuana smoking on group interaction and individual behavior. *Compr Psychiatry*. 1979;20(5):427–432. doi:10.1016/0010-440X(79)90027-0 PubMed
- SR51. Budney AJ, Hughes JR, Moore BA, et al. Review of the validity and significance of cannabis withdrawal syndrome. *Am J Psychiatry*. 2004;161(11):1967–1977. doi:10.1176/appi.ajp.161.11.1967 PubMed
- SR52. Budney AJ, Vandrey RG, Hughes JR, et al. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. *Drug Alcohol Depend*. 2007;86(1):22–29. doi:10.1016/j.drugalcdep.2006.04.014 PubMed
- SR53. Haney M. The marijuana withdrawal syndrome: diagnosis and treatment. *Curr Psychiatry Rep*. 2005;7(5):360–366. doi:10.1007/s11920-005-0036-1 PubMed
- SR54. Kouri EM, Pope HG Jr, Lukas SE. Changes in aggressive behavior during withdrawal from long-term marijuana use. *Psychopharmacology (Berl)*. 1999;143(3):302–308. doi:10.1007/s002130050951 PubMed
- SR55. Haney M, Hart CL, Vosburg SK, et al. Marijuana withdrawal in humans: effects of oral THC or divalproex. *Neuropsychopharmacology*. 2004;29(1):158–170. doi:10.1038/sj.npp.1300310 PubMed
- SR56. Clapper JR, Mangieri RA, Piomelli D. The endocannabinoid system as a target for the treatment of cannabis dependence. *Neuropharmacology*. 2009;56(suppl 1):235–243. doi:10.1016/j.neuropharm.2008.07.018 PubMed
- SR57. Sim-Selley LJ. Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. *Crit Rev Neurobiol*. 2003;15(2):91–119. doi:10.1615/CritRevNeurobiol.v15.i2.10 PubMed
- SR58. González S, Cebeira M, Fernández-Ruiz J. Cannabinoid tolerance and dependence: a review of studies in laboratory animals. *Pharmacol Biochem Behav*. 2005;81(2):300–318. doi:10.1016/j.pbb.2005.01.028 PubMed
- SR59. Martin BR, Sim-Selley LJ, Selley DE. Signaling pathways involved in the development of cannabinoid tolerance. *Trends Pharmacol Sci*. 2004;25(6):325–330. doi:10.1016/j.tips.2004.04.005 PubMed
- SR60. Rodríguez de Fonseca F, Gorriti MA, Fernández-Ruiz JJ, et al. Downregulation of rat brain cannabinoid binding sites after chronic delta 9-tetrahydrocannabinol treatment. *Pharmacol Biochem Behav*. 1994;47(1):33–40. doi:10.1016/0091-3057(94)90108-2 PubMed
- SR61. Breivogel CS, Childers SR, Deadwyler SA, et al. Chronic delta9-tetrahydrocannabinol treatment produces a time-dependent loss of cannabinoid receptors and cannabinoid receptor-activated G proteins in rat brain. *J Neurochem*. 1999;73(6):2447–2459. doi:10.1046/j.1471-4159.1999.0732447.x PubMed
- SR62. Oviedo A, Glowa J, Herkenham M. Chronic cannabinoid administration alters cannabinoid receptor binding in rat brain: a quantitative autoradiographic study. *Brain Res*. 1993;616(1–2):293–302. doi:10.1016/0006-8993(93)90220-H PubMed
- SR63. Sim-Selley LJ, Martin BR. Effect of chronic administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-[1-naphthalenyl]methanone mesylate (WIN55,212-2) or delta(9)-tetrahydrocannabinol on cannabinoid receptor adaptation in mice. *J Pharmacol Exp Ther*. 2002;303(1):36–44. doi:10.1124/jpet.102.035618 PubMed
- SR64. Breivogel CS, Scates SM, Beletskaya IO, et al. The effects of delta9-tetrahydrocannabinol physical dependence on brain cannabinoid receptors. *Eur J Pharmacol*. 2003;459(2–3):139–150. doi:10.1016/S0014-2999(02)02854-6 PubMed

- SR65. McKinney DL, Cassidy MP, Collier LM, et al. Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9-tetrahydrocannabinol. *J Pharmacol Exp Ther.* 2008;324(2):664–673. [doi:10.1124/jpet.107.130328](https://doi.org/10.1124/jpet.107.130328) [PubMed](#)
- SR66. Villares J. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. *Neuroscience.* 2007;145(1):323–334. [doi:10.1016/j.neuroscience.2006.11.012](https://doi.org/10.1016/j.neuroscience.2006.11.012) [PubMed](#)
- SR67. Ceccarini J, Kuepper R, Kemels D, et al. [F]MK-9470 PET measurement of cannabinoid CB receptor availability in chronic cannabis users [published online ahead of print December 27, 2013]. *Addict Biol.* 2015;20(2):357–367. [doi:10.1111/adb.12116](https://doi.org/10.1111/adb.12116) [PubMed](#)
- SR68. Sim LJ, Hampson RE, Deadwyler SA, et al. Effects of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated [35S]GTPgammaS autoradiography in rat brain. *J Neurosci.* 1996;16(24):8057–8066. [PubMed](#)
- SR69. Romero J, Berrendero F, Manzanares J, et al. Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta9-tetrahydrocannabinol. *Synapse.* 1998;30(3):298–308. [doi:10.1002/\(SICI\)1098-2396\(199811\)30:3<298::AID-SYN7>3.0.CO;2-6](https://doi.org/10.1002/(SICI)1098-2396(199811)30:3<298::AID-SYN7>3.0.CO;2-6) [PubMed](#)
- SR70. Gibbs M, Winsper C, Marwaha S, et al. Cannabis use and mania symptoms: a systematic review and meta-analysis. *J Affect Disord.* 2015;171:39–47. [doi:10.1016/j.jad.2014.09.016](https://doi.org/10.1016/j.jad.2014.09.016) [PubMed](#)
- SR71. Kvitland LR, Melle I, Aminoff SR, et al. Continued cannabis use at one year follow up is associated with elevated mood and lower global functioning in bipolar I disorder. *BMC Psychiatry.* 2015;15(1):11. [doi:10.1186/s12888-015-0389-x](https://doi.org/10.1186/s12888-015-0389-x) [PubMed](#)
- SR72. Bally N, Zullino D, Aubry JM. Cannabis use and first manic episode. *J Affect Disord.* 2014;165:103–108. [doi:10.1016/j.jad.2014.04.038](https://doi.org/10.1016/j.jad.2014.04.038) [PubMed](#)
- SR73. Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: a review. *Psychopharmacology (Berl).* 2006;188(4):425–444. [doi:10.1007/s00213-006-0508-y](https://doi.org/10.1007/s00213-006-0508-y) [PubMed](#)
- SR74. Ranganathan M, Carbuto M, Braley G, et al. Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. *Int J Neuropsychopharmacol.* 2012;15(9):1251–1264. [doi:10.1017/S1461145711001830](https://doi.org/10.1017/S1461145711001830) [PubMed](#)
- SR75. Sewell RA, Schnakenberg A, Elander J, et al. Acute effects of THC on time perception in frequent and infrequent cannabis users. *Psychopharmacology (Berl).* 2013;226(2):401–413. [doi:10.1007/s00213-012-2915-6](https://doi.org/10.1007/s00213-012-2915-6) [PubMed](#)
- SR76. D'Souza DC, Fridberg DJ, Skosnik PD, et al. Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans. *Neuropsychopharmacology.* 2012;37(7):1632–1646. [doi:10.1038/npp.2012.8](https://doi.org/10.1038/npp.2012.8) [PubMed](#)
- SR77. Milstein SL, MacCannell K, Karr G, et al. Marijuana-produced impairments in coordination. Experienced and nonexperienced subjects. *J Nerv Ment Dis.* 1975;161(1):26–31. [doi:10.1097/00005053-197507000-00003](https://doi.org/10.1097/00005053-197507000-00003) [PubMed](#)
- SR78. Kvålseth TO. Effects of marijuana on human reaction time and motor control. *Percept Mot Skills.* 1977;45(3 pt 1):935–939. [doi:10.2466/pms.1977.45.3.935](https://doi.org/10.2466/pms.1977.45.3.935) [PubMed](#)
- SR79. Berghaus G, Schultz E, Szegedi A. Cannabis und fahrtüchtigkeit. Ergebnisse der experimentelle forschung. In: Berghaus G, Krüger HP, eds. *Cannabis im Straßenverkehr.* Stuttgart, Germany: Gustav Fisher Verlag; 1998a:73–97.
- SR80. Dornbush RL, Fink M, Freedman AM. Marijuana, memory, and perception. *Am J Psychiatry.* 1971;128(2):194–197. [doi:10.1176/ajp.128.2.194](https://doi.org/10.1176/ajp.128.2.194) [PubMed](#)
- SR81. Moskowitz H, Shea R, Burns M. Effect of marihuana on the psychological refractory period. *Percept Mot Skills.* 1974;38(3):959–962. [doi:10.2466/pms.1974.38.3.959](https://doi.org/10.2466/pms.1974.38.3.959) [PubMed](#)
- SR82. Borg J, Gershon S, Alpert M. Dose effects of smoked marihuana on human cognitive and motor functions. *Psychopharmacologia.* 1975;42(3):211–218. [doi:10.1007/BF00421258](https://doi.org/10.1007/BF00421258) [PubMed](#)
- SR83. Peters BA, Lewis EG, Dustman RE, et al. Sensory, perceptual, motor and cognitive functioning and subjective reports following oral administration of delta9-tetrahydrocannabinol. *Psychopharmacologia.* 1976;47(2):141–148. [doi:10.1007/BF00735812](https://doi.org/10.1007/BF00735812) [PubMed](#)
- SR84. Schaefer CF, Gunn CG, Dubowski KM. Dose-related heart-rate, perceptual, and decisional changes in man following marihuana smoking. *Percept Mot Skills.* 1977;44(1):3–16. [doi:10.2466/pms.1977.44.1.3](https://doi.org/10.2466/pms.1977.44.1.3) [PubMed](#)
- SR85. Peeke SC, Jones RT, Stone GC. Effects of practice on marijuana-induced changes in reaction time. *Psychopharmacology (Berl).* 1976;48(2):159–163. [doi:10.1007/BF00423255](https://doi.org/10.1007/BF00423255) [PubMed](#)
- SR86. Stillman RC, Wolkowitz O, Weingartner H, et al. Marijuana: differential effects on right and left hemisphere functions in man. *Life Sci.* 1977;21(12):1793–1799. [doi:10.1016/0024-3205\(77\)90160-6](https://doi.org/10.1016/0024-3205(77)90160-6) [PubMed](#)
- SR87. Tapert SF, Schweinsburg AD, Drummond SP, et al. Functional MRI of inhibitory processing in abstinent adolescent marijuana users. *Psychopharmacology (Berl).* 2007;194(2):173–183. [doi:10.1007/s00213-007-0823-y](https://doi.org/10.1007/s00213-007-0823-y) [PubMed](#)
- SR88. D'Souza DC, Braley G, Blaise R, et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. *Psychopharmacology (Berl).* 2008;198(4):587–603. [doi:10.1007/s00213-007-1042-2](https://doi.org/10.1007/s00213-007-1042-2) [PubMed](#)
- SR89. Morrison PD, Zois V, McKeown DA, et al. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. *Psychol Med.* 2009;39(10):1607–1616. [doi:10.1017/S0033291709005522](https://doi.org/10.1017/S0033291709005522) [PubMed](#)
- SR90. Hanson KL, Winward JL, Schweinsburg AD, et al. Longitudinal study of cognition among adolescent marijuana users over three weeks of abstinence. *Addict Behav.* 2010;35(11):970–976. [doi:10.1016/j.addbeh.2010.06.012](https://doi.org/10.1016/j.addbeh.2010.06.012) [PubMed](#)
- SR91. Dumont GJ, van Hasselt JG, de Kam M, et al. Acute psychomotor, memory and subjective effects of MDMA and THC co-administration over time in healthy volunteers. *J Psychopharmacol.* 2011;25(4):478–489. [doi:10.1177/0269881110376687](https://doi.org/10.1177/0269881110376687) [PubMed](#)
- SR92. Solowij N, Jones KA, Rozman ME, et al. Verbal learning and memory in adolescent cannabis users, alcohol users and non-users. *Psychopharmacology (Berl).* 2011;216(1):131–144. [doi:10.1007/s00213-011-2203-x](https://doi.org/10.1007/s00213-011-2203-x) [PubMed](#)
- SR93. Ballard ME, Gallo DA, de Wit H. Psychoactive drugs and false memory: comparison of dextroamphetamine and δ-9-tetrahydrocannabinol on false recognition. *Psychopharmacology (Berl).* 2012;219(1):15–24. [doi:10.1007/s00213-011-2374-5](https://doi.org/10.1007/s00213-011-2374-5) [PubMed](#)
- SR94. Anderson BM, Rizzo M, Block RI, et al. Sex, drugs, and cognition: effects of marijuana. *J Psychoactive Drugs.* 2010;42(4):413–424. [doi:10.1080/02791072.2010.10400704](https://doi.org/10.1080/02791072.2010.10400704) [PubMed](#)
- SR95. Evans MA, Martz R, Brown DJ, et al. Impairment of performance with low doses of marihuana. *Clin Pharmacol Ther.* 1973;14(6):936–940. [doi:10.1002/cpt.1973146936](https://doi.org/10.1002/cpt.1973146936) [PubMed](#)
- SR96. Roth WT, Tinklenberg JR, Whitaker CA, et al. The effect of marihuana on tracking task performance. *Psychopharmacologia.* 1973;33(3):259–265. [doi:10.1007/BF00423060](https://doi.org/10.1007/BF00423060) [PubMed](#)
- SR97. Burns M, Moskowitz H. Alcohol, marihuana and skills performance. Presented at the 8th International Council on Alcohol, Drugs and Traffic Safety Conference; Stockholm, Sweden; 1980: 954-968. http://www.icadtsinternational.com/documents/?category=08th_T1980_Stockholm

- SR98. D'Souza DC, Abi-Saab WM, Madonick S, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. *Biol Psychiatry*. 2005;57(6):594–608. doi:10.1016/j.biopsych.2004.12.006 PubMed
- SR99. Loewe S. *The Marihuana Problem in the City of New York: The Mayor's Committee on Marihuana*. Lancaster, PA: Jacques Cattel Press; 1944:149–212.
- SR100. Clark LD, Hughes R, Nakashima EN. Behavioral effects of marihuana: experimental studies. *Arch Gen Psychiatry*. 1970;23(3):193–198. doi:10.1001/archpsyc.1970.01750030001001 PubMed
- SR101. Kiplinger GF, Manno JE, Rodda BE, et al. Dose-response analysis of the effects of tetrahydrocannabinol in man. *Clin Pharmacol Ther*. 1971;12(4):650–657. doi:10.1002/cpt1971124650 PubMed
- SR102. Rafaelsen L, Christrup H, Bech P, et al. Effects of cannabis and alcohol on psychological tests. *Nature*. 1973;242(5393):117–118. doi:10.1038/242117a0 PubMed
- SR103. Berghaus G, Krüger HP, Vollrath M. Beeinträchtigung fahrrelevanter leistung nach rauchen von cannabis und alcoholconsum: eine vergleichende metaanalyse experimenteller studien. In: Berghaus G, Krüger HP, eds. *Cannabis im Straßenverkehr*. Stuttgart, Germany: Gustav Fisher Verlag; 1998b:99–111.
- SR104. Crane NA, Schuster RM, Fusar-Poli P, et al. Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. *Neuropsychol Rev*. 2013;23(2):117–137. doi:10.1007/s11065-012-9222-1 PubMed
- SR105. Ramaekers JG, Berghaus G, van Laar M, et al. Dose related risk of motor vehicle crashes after cannabis use. *Drug Alcohol Depend*. 2004;73(2):109–119. doi:10.1016/j.drugalcdep.2003.10.008 PubMed
- SR106. Rogeberg O. Correlations between cannabis use and IQ change in the Dunedin cohort are consistent with confounding from socioeconomic status. *Proc Natl Acad Sci U S A*. 2013;110(11):4251–4254. doi:10.1073/pnas.1215678110 PubMed
- SR107. Daly M. Personality may explain the association between cannabis use and neuropsychological impairment. *Proc Natl Acad Sci U S A*. 2013;110(11):E979. doi:10.1073/pnas.1218571110 PubMed
- SR108. Moffitt TE, Meier MH, Caspi A, et al. Reply to Rogeberg and Daly: no evidence that socioeconomic status or personality differences confound the association between cannabis use and IQ decline. *Proc Natl Acad Sci U S A*. 2013;110(11):E980–E982. doi:10.1073/pnas.1300618110 PubMed
- SR109. Jager G, Kahn RS, Van Den Brink W, et al. Long-term effects of frequent cannabis use on working memory and attention: an fMRI study. *Psychopharmacology (Berl)*. 2006;185(3):358–368. doi:10.1007/s00213-005-0298-7 PubMed
- SR110. Solowij N. Do cognitive impairments recover following cessation of cannabis use? *Life Sci*. 1995;56(23–24):2119–2126. doi:10.1016/0024-3205(95)00197-E PubMed
- SR111. Hall W, Solowij N. Adverse effects of cannabis. *Lancet*. 1998;352(9140):1611–1616. doi:10.1016/S0140-6736(98)05021-1 PubMed
- SR112. Fried PA, Watkinson B, Gray R. Neurocognitive consequences of marihuana—a comparison with pre-drug performance. *Neurotoxicol Teratol*. 2005;27(2):231–239. doi:10.1016/j.ntt.2004.11.003 PubMed
- SR113. Robbe H. Marijuana's impairing effects on driving are moderate when taken alone but severe when combined with alcohol. *Hum Psychopharmacol*. 1998;13(suppl 2):S70–S78. doi:10.1002/(SICI)1099-1077(199811)13:2+<S70::AID-HUP50>3.0.CO;2-R
- SR114. Bosker WM, Theunissen EL, Conen S, et al. A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid. *Psychopharmacology (Berl)*. 2012;223(4):439–446. doi:10.1007/s00213-012-2732-y PubMed
- SR115. Bosker WM, Kuypers KP, Theunissen EL, et al. Medicinal $\Delta(9)$ -tetrahydrocannabinol (dronabinol) impairs on-the-road driving performance of occasional and heavy cannabis users but is not detected in Standard Field Sobriety Tests. *Addiction*. 2012;107(10):1837–1844. doi:10.1111/j.1360-0443.2012.03928.x PubMed
- SR116. Lenné MG, Dietze PM, Triggs TJ, et al. The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand. *Accid Anal Prev*. 2010;42(3):859–866. doi:10.1016/j.aap.2009.04.021 PubMed
- SR117. Anderson BM, Rizzo M, Block RI, et al. Sex differences in the effects of marijuana on simulated driving performance. *J Psychoactive Drugs*. 2010;42(1):19–30. doi:10.1080/02791072.2010.10399782 PubMed
- SR118. Smiley AM. Marijuana: on-road and driving simulator studies. *Alcohol Drugs Driving*. 1986;2(3–4):121–134.
- SR119. Terhune KW, Fell JC. *The Role of Alcohol, Marijuana and Other Drugs in the Accidents of Injured Drivers*. Buffalo, New York: 1982. Report No: Tech. Rep. under Contract No. DOT-HS-5-01179.
- SR120. Terhune KW, Ippolito CA, Hendriks DL, et al. The incidence and role of drugs in fatally injured drivers; 1992. Report No: Final Report under Contract No. DTNH 22-88-C-07069.
- SR121. Mura P, Kintz P, Ludes B, et al. Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subjects: results of a French collaborative study. *Forensic Sci Int*. 2003;133(1–2):79–85. doi:10.1016/S0379-0738(03)00052-5 PubMed
- SR122. Drummer OH, Gerostamoulos J, Batziris H, et al. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. *Accid Anal Prev*. 2004;36(2):239–248. PubMed
- SR123. Dubois S, Mullen N, Weaver B, et al. The combined effects of alcohol and cannabis on driving: impact on crash risk. *Forensic Sci Int*. 2015;248:94–100. doi:10.1016/j.forsciint.2014.12.018 PubMed
- SR124. Aldington S, Harwood M, Cox B, et al; Cannabis and Respiratory Disease Research Group. Cannabis use and risk of lung cancer: a case-control study. *Eur Respir J*. 2008;31(2):280–286. doi:10.1183/09031936.00065707 PubMed
- SR125. Callaghan RC, Allebeck P, Sidorchuk A. Marijuana use and risk of lung cancer: a 40-year cohort study. *Cancer Causes Control*. 2013;24(10):1811–1820. doi:10.1007/s10552-013-0259-0 PubMed
- SR126. Hashibe M, Morgenstern H, Cui Y, et al. Marijuana use and the risk of lung and upper aerodigestive tract cancers: results of a population-based case-control study. *Cancer Epidemiol Biomarkers Prev*. 2006;15(10):1829–1834. doi:10.1158/1055-9965.EPI-06-0330 PubMed
- SR127. Hall W, Degenhardt L. Adverse health effects of non-medical cannabis use. *Lancet*. 2009;374(9698):1383–1391. doi:10.1016/S0140-6736(09)61037-0 PubMed
- SR128. Yamaori S, Koeda K, Kushihara M, et al. Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. *Drug Metab Pharmacokinet*. 2012;27(3):294–300. doi:10.2133/dmpk.DMPK-11-RG-107 PubMed
- SR129. Yamaori S, Okamoto Y, Yamamoto I, et al. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. *Drug Metab Dispos*. 2011;39(11):2049–2056. doi:10.1124/dmd.111.041384 PubMed

- SR130. Jiang R, Yamaori S, Okamoto Y, et al. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. *Drug Metab Pharmacokinet.* 2013;28(4):332–338. [doi:10.2133/dmpk.DMPK-12-RG-129](https://doi.org/10.2133/dmpk.DMPK-12-RG-129) [PubMed](#)
- SR131. Yamaori S, Ebisawa J, Okushima Y, et al. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. *Life Sci.* 2011;88(15–16):730–736. [doi:10.1016/j.lfs.2011.02.017](https://doi.org/10.1016/j.lfs.2011.02.017) [PubMed](#)